Discontinuing Emtricitabine-Tenofovir in End-of-Life Care
Yes, it is feasible and appropriate to discontinue emtricitabine-tenofovir in patients with a prognosis of weeks to months, with critical attention to hepatitis B co-infection status.
Primary Consideration: Hepatitis B Co-infection
The most critical factor determining whether you can safely stop emtricitabine-tenofovir is hepatitis B virus (HBV) co-infection status:
If HBV Co-infected (HBsAg Positive):
Do NOT discontinue emtricitabine-tenofovir without careful consideration. Discontinuation can precipitate severe acute hepatitis B exacerbations, including liver decompensation and liver failure, particularly in patients with cirrhosis 1, 2. The FDA label explicitly warns that severe acute exacerbations of hepatitis B have been reported in HIV/HBV co-infected patients who discontinued emtricitabine, requiring close clinical and laboratory monitoring for at least several months after stopping treatment 2.
- If discontinuation is necessary: Consider initiating alternative HBV-suppressive therapy 3
- Monitor intensively: Liver function tests and HBV DNA levels for several months post-discontinuation 1
- Highest risk: Patients with advanced liver disease or cirrhosis 1
If HBV Negative:
Discontinuation is feasible and appropriate in the palliative context. There are no specific guidelines addressing antiretroviral discontinuation in end-of-life care, but the principles of palliative medicine support medication deprescribing when:
- Life expectancy is weeks to months
- The medication no longer aligns with goals of care
- Reducing pill burden improves quality of life
Clinical Decision Algorithm
Step 1: Check HBsAg status (if not recently documented)
- Positive → Proceed with extreme caution (see above)
- Negative → Safe to discontinue for comfort-focused care
Step 2: Consider patient-specific factors:
- Current HIV viral load: If virologically suppressed and prognosis is truly weeks to months, viral rebound is unlikely to cause clinical harm within this timeframe
- CD4 count: Irrelevant in this context given short prognosis
- Pill burden and quality of life: Primary consideration in palliative care
- Patient/family preferences: Essential to discuss goals of care
Step 3: If discontinuing:
- No specific tapering required—can stop abruptly if HBV negative
- Continue monitoring for symptoms only (not laboratory values in true end-of-life care)
- Focus on symptom management and comfort measures
Important Caveats
Renal function considerations: While emtricitabine requires dose adjustment in renal impairment 2, this is irrelevant when discontinuing for palliative reasons.
Resistance concerns: The guidelines emphasize maintaining viral suppression to prevent resistance 3, 1, but this consideration becomes moot when prognosis is measured in weeks to months rather than years.
PrEP vs. Treatment context: The evidence provided discusses PrEP discontinuation protocols (continuing 1 week after last exposure) 1, 3, which is not applicable to your treatment scenario.
Bottom Line
Discontinue emtricitabine-tenofovir in HBV-negative patients with weeks-to-months prognosis to reduce pill burden and align with palliative goals of care. In HBV co-infected patients, either continue therapy or substitute alternative HBV-suppressive treatment to prevent potentially fatal hepatic decompensation.